UroGen Q2 Jelmyto revenue $16.6M (+28% YoY); reaffirms FY22 guidance $70-80M

UroGen Pharma Ltd.

Q2 Jelmyto net revenue $16.6M, up 22% QoQ and 28% YoY from $13.0M.
Net loss $26.7M ($1.18/share) vs $26.2M ($1.17/share) in Q2 2021.
Cash and marketable securities $112.4M as of June 30, 2022.
Reaffirms FY2022 Jelmyto revenue guidance of $70-80M; reduces operating expense forecast to $130-140M.
Enrollment in Phase 3 ENVISION trial for UGN-102 on track for completion by end of 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.